You are here

  • Home
  • Archive
  • Volume 17, Issue 7
  • Concurrent existence of cold agglutinin disease and ANCA-associated vasculitis with fulminant pulmonary-renal syndrome poses significant treatment challenges

Article Text

Article menu
Download PDFPDF
Renal medicine
Concurrent existence of cold agglutinin disease and ANCA-associated vasculitis with fulminant pulmonary-renal syndrome poses significant treatment challenges
  1. Moritz Schanz1,
  2. Benedikt Wagner2,
  3. Raffi Bekeredjian2 and
  4. Joerg Latus1
  1. 1 General Internal Medicine and Nephrology, Robert Bosch Hospital, Stuttgart, Germany
  2. 2 Department of Cardiology and Intensive Care Medicine, Robert Bosch Hospital, Stuttgart, Baden-Württemberg, Germany
  1. Correspondence to Dr Moritz Schanz; moritz.schanz{at}rbk.de

Abstract

We present a case of a man in his 40s with pulmonary-renal syndrome due to myeloperoxidase-positive antineutrophil cytoplasmic antibodies-associated vasculitis and concurrent cold agglutinin disease, a combination that has not yet been described in the literature. The fulminant course of the disease, including the need for kidney replacement therapy and mechanical ventilation posed a significant treatment challenge due to haemolytic complications.

  • Renal system
  • Adult intensive care
  • Acute renal failure
  • Dialysis
  • Vasculitis

https://doi.org/10.1136/bcr-2023-257859

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: MS, BW, RB and JL. The following authors gave final approval of the manuscript: MS, BW, RB and JL.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests JL received consulting/lecture fees from Vifor Pharma.

    • Provenance and peer review Not commissioned; externally peer reviewed.